Ricardo Villalobos-Valencia

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Richard T. Penson, Ricardo Villalobos-Valencia, David Cibula et al. · Journal of Clinical Oncology · 2020 · 295 citations · Full text

Medicine, Oncology, Pharmacology +16

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Tae Won Kim, Anneli Elme, Zvonko Kusić et al. · British Journal of Cancer · 2016 · 72 citations · Full text

Medicine, Cancer Biology, Gastrointestinal Oncology +14

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

R. Dent, Fabrice André, Anthony Gonçalvès et al. · Annals of Oncology · 2024 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17